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On January 21, 2010, the American Hepato-Pancreato-Biliary
Association convened a Consensus Conference on the multidisci-
plinary treatment of hepatocellular cancer (HCC). The conference
was cosponsored by the Society of Surgical Oncology, the Society
for Surgery of the Alimentary Tract, and The University of Texas
M.D.AndersonCancerCenter.The goals of this conferencewere to
address knowledge gaps in the areas of the optimal preparation of
patients with HCC for operative therapy, the best methods to
control HCC while awaiting liver transplantation, and developing
a multidisciplinary approach to these patients with the imple-
mentation of novel systemic therapies. This meeting took place
over 1 day and was divided into three sessions addressing (1)
pretreatment assessment, (2) surgical treatment, and (3) combined
modality therapy.
This issue of HPB has three manuscripts outlining the consen-
sus statements1,2,3 with each manuscript accompanied by an edi-
torial. The methods used in this consensus conference have been
described previously.4,5 Following consultation among experts
from the three sponsoring societies, a group of experts was iden-
tified and invited to participate in this conference. Each expert was
asked to present on a given area and to outline two or three
consensus statements at the end of his or her presentation.A panel
of content experts commented on the consensus statements, and
then the audience was given the opportunity to comment on the
consensus statements. After the symposium, three manuscripts,
each summarizing one of the sessions, were written by the speak-
ers and session co-chairs. Each manuscript was then given to
the corresponding session panelists, who wrote a brief editorial-
highlighting areas of controversy and importance and providing
alternative perspectives.
HCC is one of the commonest malignancies in the world.
Its management is made complex by the interplay of tumor
characteristics and the health and underlying function of
both the patient and the liver. The pretreatment consensus
statements tackle some of the issues around proper staging,
the optimal methods of imaging and staging these tumors,
the appropriate use of adjunctive procedures to minimize
perioperative risk for these patients – which includes the use
of portal vein embolization and hepatic volumetric assessment,
and defining resectability in light of patient, tumor, and liver
factors. The second session on the surgical management of
these patients deals with the appropriate use of radiofrequency
ablation in the treatment armamentarium of these patients,
optimal technical considerations when performing hepatic resec-
tion, the use of bridging therapies prior to hepatic transplan-
tation, and the criteria for transplantation in light of patient,
liver, and tumor factors. The third and final session focused
on the use of combined modality therapy in the setting of a
multidisciplinary team environment; it specifically addresses
the use of transarterial chemoembolization, systemic therapies
including sorafenib, Yttrium 90 microembolization, and the
novel use of radiotherapy in these patients. Finally, areas requir-
ing further study have been identified and highlighted, with
a strong emphasis placed on the vast majority of patients that
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are not candidates for resection, transplantation, ablation or
regional therapies; and consequently the urgent need for novel
systemic therapies. The conference participants and the consen-
sus statements generated are reflective of the importance of
ongoing collaborative multidisciplinary care of patients with
HCC.
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